- Home
- ORIC
as 10-30-2025 9:34am EST
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 1.1B | IPO Year: | 2020 |
| Target Price: | $16.57 | AVG Volume (30 days): | 1.5M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.89 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.90 - $14.93 | Next Earning Date: | 11-06-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Oric Pharmaceuticals Inc. (ORIC)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Chacko Jacob | ORIC | PRESIDENT AND CEO | Oct 6 '25 | Sell | $12.32 | 37,461 | $461,519.52 | 531,419 | |
| Piscitelli Dominic | ORIC | Chief Financial Officer | Oct 6 '25 | Sell | $14.52 | 11,000 | $159,718.90 | 48,317 | |
| Chacko Jacob | ORIC | PRESIDENT AND CEO | Oct 1 '25 | Sell | $12.05 | 53,001 | $638,805.15 | 531,419 | |
| Chacko Jacob | ORIC | PRESIDENT AND CEO | Sep 30 '25 | Sell | $12.01 | 34,538 | $414,749.57 | 531,419 | |
| Chacko Jacob | ORIC | PRESIDENT AND CEO | Sep 22 '25 | Sell | $10.80 | 125,000 | $1,349,937.50 | 531,419 |
Latest Oric Pharmaceuticals Inc. News
ORIC Breaking Stock News: Dive into ORIC Ticker-Specific Updates for Smart Investing
Simply Wall St.
a month ago
We're Not Very Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Rate
MT Newswires
a month ago
Oric Pharmaceuticals Insider Sold Shares Worth $1,053,555, According to a Recent SEC Filing
Investor's Business Daily
a month ago
Oric Pharmaceuticals Stock Scores RS Rating Upgrade
GlobeNewswire
2 months ago
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Argus Research
4 months ago
Daily – Vickers Top Buyers & Sellers for 06/24/2025
Zacks
4 months ago
All You Need to Know About Oric Pharmaceuticals (ORIC) Rating Upgrade to Buy
Zacks
4 months ago
Does Oric Pharmaceuticals (ORIC) Have the Potential to Rally 104.99% as Wall Street Analysts Expect?
Zacks
5 months ago
What Makes Oric Pharmaceuticals, Inc. (ORIC) a Strong Momentum Stock: Buy Now?
Compare ORIC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ORIC Oric Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.